Findings could lead to advances in the use of bacteria to treat intestinal diseases, among other applications

Israeli-German partnership aims to replace animal experiments with advanced liver-on-chip devices

Study finds state policies influence vaccination, disease outbreak rates.

Sanofi, a global health care company, recently signed an agreement with the University of Texas System to fund selected research programs focused on the early stages of drug discovery.

A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.

Most drug discovery efforts begin with a biological target—the molecule inside the body whose activity the drug is expected to enhance or diminish. Assurance that the target is pharmacologically accessible and responsible in some way for the disease in question is based on target validation studies.

The Salk Institute and Sanford Burnham Prebys Medical Discovery Institute created a compound that stops a cellular recycling process.

Dreaded bacterial-related diseases have killed untold numbers of humans over the centuries. Today, two million illnesses and nearly 23,000 deaths can be attributed to antibiotic-resistant bacteria throughout the United States, say the Centers for Disease Control and Prevention.

In a finding important for preventing the development of antibiotic-resistant superbugs, researchers at the University of Virginia School of Medicine and 22 other institutions have determined that the duration of antibiotic treatment for complicated abdominal infections can be cut by half and remain equally effective.

There’s an urgent demand for new antimicrobial compounds that are effective against constantly emerging drug-resistant bacteria. Two robotic chemical-synthesizing machines, named Symphony X and Overture, have joined the search. Their specialty is creating custom nanoscale structures that mimic nature’s proven designs. They’re also fast, able to assemble dozens of compounds at a time.

Meet Doug Frantz. The Max and Minnie Tomerlin Voelcker Distinguished Professor in Chemistry was selected by the pharmaceutical company Eli Lilly & Co. to receive its Outstanding Open Innovation Drug Discovery Collaborator Award.

Janssen Pharmaceutical gift broadens strategic collaboration with School of Engineering.